A first-of-its-kind study on molecular interactions by biomedical engineers will make it easier and more efficient for scientists to develop new medicines and other therapies for diseases such as cancer, HIV, and autoimmune diseases.
A first-of-its-kind study on molecular interactions by biomedical engineers will make it easier and more efficient for scientists to develop new medicines and other therapies for diseases such as cancer, HIV, and autoimmune diseases.